Interaction of amphotericin B lipid formulations and triazoles with human polymorphonuclear leucocytes for antifungal activity against Zygomycetes.
The frequency of zygomycosis has increased considerably over recent years mainly in immunocompromised and diabetic patients. Little is known about the effects of host innate immunity against different Zygomycetes especially under the influence of antifungal agents. The antifungal activity of human polymorphonuclear leucocytes (PMN) in combination with liposomal amphotericin B (LAMB), amphotericin B lipid complex (ABLC), voriconazole (VRC) and posaconazole (PSC) against Rhizopus oryzae and Rhizopus microsporus, frequently isolated Zygomycetes, were studied and compared with Absidia corymbifera, a less pathogenic Zygomycete. Antifungal activity was evaluated as per cent of hyphal damage using the XTT metabolic assay. While A. corymbifera was more susceptible to PMN than the other two Zygomycetes, R. microsporus appeared to be the most susceptible to combined effects of amphotericin B formulations and VRC with PMN. LAMB exhibited synergistic activity with PMN in inducing hyphal damage to R. microsporus but not to the other fungi. In contrast, ABLC exhibited synergistic or additive activity with PMN against all three fungi. Among triazoles, only VRC exhibited additive effect with PMN against R. microsporus. Lipid formulations of amphotericin B and particularly ABLC interact with PMN predominantly in inducing augmented hyphal damage to three different species of Zygomycetes.
Simitsopoulou
Maria
M
Laboratory of Infectious Diseases, Third Department of Pediatrics, Aristotle University, Hippokration Hospital, Thessaloniki, Greece.
Roilides
Emmanuel
E
Maloukou
Avgi
A
Gil-Lamaignere
Cristina
C
Walsh
Thomas J
TJ
D020095:Absidia / Q000187:drug effects* / Q000254:growth & development; D000328:Adult; D000666:Amphotericin B / Q000494:pharmacology*; D000935:Antifungal Agents / Q000494:pharmacology*; D004338:Drug Combinations; D004347:Drug Interactions; D006801:Humans; D025301:Hyphae / Q000187:drug effects / Q000254:growth & development; D008081:Liposomes / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D009504:Neutrophils / Q000276:immunology*; D010713:Phosphatidylcholines / Q000494:pharmacology*; D010715:Phosphatidylglycerols / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology; D012233:Rhizopus / Q000187:drug effects* / Q000254:growth & development; D014230:Triazoles / Q000494:pharmacology*; D065819:Voriconazole
D000935:Antifungal Agents; D004338:Drug Combinations; D008081:Liposomes; D010713:Phosphatidylcholines; D010715:Phosphatidylglycerols; D011743:Pyrimidines; D014230:Triazoles; C068538:liposomal amphotericin B; C101425:posaconazole; D000666:Amphotericin B; D065819:Voriconazole